

Investor Relations News

Bản tin nhà đầu tư **IMEXPHARM**

04-19



IMEXPHARM STOCK MOVEMENT IN APRIL 2019
IMEXPHARM OPERATION IN APRIL, 2019



INVESTOR RELATIONS (IR) - IMEXPHARM CORPORATION

No.4, 30/4 Street, Cao Lanh City, Dong Thap Province

TEL: (84.28) 3866 9856

Website: www.imexpharm.com

CONTENTS

- I. IMEXPHARM STOCK MOVEMENT IN APRIL 2019**
 - 1. IMP shares in April 2019
 - 2. IMP shares price compared to other listed pharmaceutical companies
 - II. IMEXPHARM OPERATION IN APRIL, 2019**
-

I. IMEXPHARM STOCK MOVEMENT IN APRIL 2019

1. IMP STOCK IN APRIL 2019

General information


Stock code	IMP
Stock exchange	HSX
Price range of 52 weeks (VND)	49,000 – 63,000
Amount of listed shares	49,421,159
Amount of current shares	49,401,159
Fields of operation	Manufacturing and trading pharmaceutical products
Value of market capitalization (as of 28 Feb, 2019)	2,563.9 billion dong
Room for foreign investors	49.00%
P/E	18
P/B	1.7
Structure of shareholders (Source: Vietnam Securities Depository, as of 05th Jun, 2018)	
-Vietnam Pharmaceutical Joint Stock Company	22.87%
-Foreign Investors	48.13%
+ Therein: Foreign Professional Investors being significant Shareholders who own more than 5% of shares	16.03%
- Special Shareholders (Board of Directors, Board of Managers, Supervisory Board, Chief Accountant, Authorized Discloser), Labor Union	3.15%
- Others	25.85%

IMP VS VNINDEX IN 04/2019


VNIndex and IMP stock in April 2019

VNIndex witnessed many fluctuations in April, 2019. VNIndex started at 988.53 points, then increased and peaked 997.56 points on 08th April; however, this figure decreased and touched the bottom of 962.3 on 18th April. But VNIndex has recovered in the days near month-end and closed at 979.64 points, dropped slightly about 1% compared to the point of the beginning of April.

On the other hand, IMP stock had stable trend when commencing at closing price of 51,500 dong/share and ending at 51,900 dong/share



IMP TRANSACTION VOLUME IN 04/2019




Transaction volume

In general, there are not many IMP transacted in April, 2019. Total transaction volume of order matching method was 180,660 shares and the average per day reached 9,508 shares. In April, IMP did not have any put through transaction.

2. IMP price movements compared to other listed pharmaceutical companies

PRICE MOVEMENT OF FIVE LISTED COMPANIES' SHARES

(Source: vndirect.com.vn)



Overall, stock prices of pharmaceutical companies in April 2019 did not have many changes. Closing price of the last transaction day compared to the one of the first traded day as following:

- IMP price increased slightly 400 dong/share from 51,500 dong/share to 51,900 dong/share.
- DHG declined 2,100 dong/share from 118,000 to 115,900 dong/share, represented the drop of 1.8%
- DMC decreased from 74,800 dong to 71,000 dong, reduced 5.1%
- TRA is the stock having deepest drop compared to the beginning of the month. This stock felt 4,100 dong/share.
- PME dropped slightly 1,000 dong/share from 58,000 to 57,000 dong/share

II. OPERATION OF IMEXPHARM IN APRIL, 2019

(Measurement unit: Billion VND)

Criteria	April, 2019	Up to April, 2019	% Plan 2019	Up to April, 2018	Growth rate
Total Net Revenue and other Incomes	73.3	349.6	24.1%	323.1	8.2%
Net revenue	72.9	346.0		318.8	8.5%
Profit before tax	11.5	56.9	25.9%	50.1	13.6%

In April, 2019 total net revenue and income of Imexpharm reached 73.3 billion dong. In which, Imexpharm products still play a significant role, accounted for over 88% in total revenue. Total revenue and income accumulated to end of April achieved 24.1% of annual plan.

Profit before tax calculated until April, 2019 was 56.9 billion dong, increased 13.6% year over year and met 26% plan set by General Meeting of Shareholders.

Although revenue and profit of IMP are growing but the rates are much lower than the expected ones. This fact boosts all employees of the Company to expand business activities in the next months to achieve targets of whole year.

In April, Imexpharm has organized Annual General Meeting 2019 to declare the business performance of 2018, strategic targets for 2019. In the meeting, 100% of attending shareholders have agreed and supported the plans that the Board of Directors and Executive Board proposed for 2019.

REVENUE AND PROFIT BEFORE TAX 04/2018 - 04/2019

